window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Opinion & Events

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Medical devices,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Terumo BCT expands access to rare disease therapies across Latin America

    Terumo Blood and Cell Technologies has announced regulatory approvals for [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    Saphnelo self-administration Phase 3 trial meets primary endpoint in systemic lupus erythematosus

    AstraZeneca has reported positive interim results from the Phase 3 [...]

    May 5, 2026
  • Clinical & Regulatory,Medical devices,Opinion & Events,Pharmaceuticals and therapeutics

    Amber Implants secures FDA clearance for VCFix spinal system

    Amber Implants has received FDA 510(k) clearance for its VCFix [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    EADV 2025: Almirall showcases real-world evidence and pipeline progress in dermatology

    Almirall, a global biopharmaceutical company focused on medical dermatology, has [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    MaaT Pharma reports strong Phase 3 results and EMA submission for Xervyteg

    MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]

    May 5, 2026
  • Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Abu Dhabi Biobank expands access to cord blood banking through NMC Healthcare partnership

    Abu Dhabi Biobank has partnered with NMC Healthcare to expand [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Opinion & Events

    TransCelerate and Tufts study finds nearly one-third of clinical trial data adds limited value

    A new collaborative study from TransCelerate BioPharma and the Tufts [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Medical devices,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    electronRx to launch app for remote respiratory disease management

    electronRx will launch its pDx app at the HLTH 2025 [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Opinion & Events,Pharmaceuticals and therapeutics

    Almirall study shows psoriasis treatment improves skin and psychological well-being

    Almirall has presented new two-year results from its POSITIVE study [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Medical devices,Opinion & Events,Pharmaceuticals and therapeutics,Therapeutic Areas

    BIG D-FOOT trial results on STIMULAN to be presented at EBJIS 2025

    Biocomposites will present new clinical data from the BIG D-FOOT [...]

    May 5, 2026
Previous678Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical & Regulatory, Therapeutic Areas
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top